Value202020212022202320242025TTMSelling/general/admin expenses9.51 M11.02 M12.21 M9.69 M4.13 M3.95 M3.95 MResearch & development47.3 M55.71 M63.95 M41.04 M8.42 M——Operating income-56.81 M-66.72 M-76.16 M-49.26 M-16.25 M-2.43 M-2.43 MNon-Operating Income, Total-3.21 M353 K-1.37 M-2.34 M493 K511 K511 KInterest expense, net of interest capitalized3.92 M03.36 M5.3 M5 000——Non-Operating Income, excl. Interest Expenses-7.13 M0-4.72 M-7.63 M493 K511 K511 KUnusual income/expense—353 K—-9 000-5 000——Pretax income-63.93 M-66.37 M-80.88 M-58.51 M-15.76 M-1.92 M-1.92 MEquity in earnings———————Taxes—————27 K—Non-controlling/minority interest———————After tax other income/expense———————Net income before discontinued operations-60.02 M-66.37 M-77.53 M-51.6 M-15.75 M-1.92 M-1.92 MDiscontinued operations———————Net income-60.02 M-66.37 M-77.53 M-51.6 M-15.75 M-1.92 M-1.92 MDilution adjustment———————Preferred dividends———————Diluted net income available to common stockholders-60.02 M-66.37 M-77.53 M-51.6 M-15.75 M-1.92 M-1.92 MBasic earnings per share (Basic EPS)——-562.5-300-38.57-0.39-0.39Diluted earnings per share (Diluted EPS)——-562.5-300-38.57-0.39-0.39Average basic shares outstanding——137.91 K172.08 K609.7 K4.91 M18.03 MDiluted shares outstanding——137.91 K172.08 K609.7 K4.91 M18.03 MEBITDA——-72.71 M-48.61 M-15.57 M——EBIT——-76.41 M-50.59 M-16.25 M——Cost of revenue———————Other cost of goods sold———————Depreciation & amortization (cash flow)4 M2.17 M3.19 M1.98 M671 K34 K34 K
Mustang Bio Inc
Mustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency.